ArticleJHEP reports : innovation in hepatology2023

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.

Stephen A Harrison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.